INS and Hyperglycemia: In Figure 4C, we show that Ins-RT-NP administration beginning at 11 weeks of age when substantial insulitis is known to exist, prevented the onset of hyperglycemia in a significant proportion of recipients compared to mice treated with microparticles that were devoid of RA, TGFβ1 and insulin B9-23 peptide, or mice treated with vehicle alone.